Pure Global
NCT06419400

A Research Study to Explore the Impact of GP Support Via Text Messages to Patients With Asthma and/or COPD

A Randomised Controlled Trial to Evaluate the Impact of Supportive Text Messages From GP Practices on Self-reported Symptoms and Inhaler Adherence in Patients With Asthma and/or Chronic Obstructive Pulmonary Disease (COPD) Who Have Been Prescribed a Preventer (Daily) Inhaler (Inhaler Trial)
Accurx·ClinicalTrials.gov·behavioralCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Asthma,COPD
Drug/Device/Intervention
Supportive text messages
Study type
Interventional
Intervention type
behavioral
Sponsor & location
Primary sponsor
Accurx
Location
Canterbury,Gravesend,Longfield,Rochester,Dudley,Stourbridge,Worsley, United Kingdom
Timeline & enrollment
Phase
N/A
Start date
Apr 01, 2022
End date
Nov 01, 2023
Enrollment
6053 participants
Primary outcome

Improved self-reported medication taking as measured by the The Medication Adherence Report Scale (MARS-5) Questionnaire

Summary

A 6-month randomised controlled trial to evaluate the impact of text message support on
 symptom control and inhaler adherence for patients with asthma and/or COPD

ICD-10 classifications
AsthmaAsthma, unspecifiedNonallergic asthmaMixed asthmaOther chronic obstructive pulmonary disease
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06419400
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06419400 through Pure Global AI's free database. This phase not specified trial is sponsored by Accurx and is currently Completed. The study focuses on Asthma,COPD. Target enrollment is 6053 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.